BELLICUM PHARMACEUTICALS INC (BLCM) Stock Analyst Earnings Estimates
NASDAQ:BLCM - Nasdaq - US0794814048 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 500K -93.00% | 6.2M 1,140.00% | 1.5M -75.81% | -100.00% | 200.41M | ||||
| EBITDA YoY % growth | -52.61M 32.62% | -24.283M 53.84% | -26.97M -11.07% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -54.08M 36.57% | -24.388M 54.90% | -26.981M -10.63% | -16.068M 40.45% | -14.462M 10.00% | -13.015M 10.00% | -11.714M 10.00% | -7.862M 32.88% | |
| Operating Margin | -10,816.00% | -393.35% | -1,798.73% | N/A | N/A | N/A | N/A | -3.92% | |
| EPS YoY % growth | -7.40 69.06% | -1.12 84.86% | -0.81 27.59% | -0.50 38.37% | -0.32 36.73% | -0.22 29.03% | -0.17 22.73% | -0.09 47.06% |
All data in USD
| Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.30 -127.54% | -0.09 60.09% | -0.04 79.70% |
| Revenue Q2Q % growth | -100.00% | -100.00% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -4.414M 32.48% | -2.206M 69.21% | -1.104M 84.96% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2023 Q2Q % growth | -0.26 -4.00% | -0.35 | 0.09 | 25.03% |
| Q4 2022 Q2Q % growth | -0.20 -282.72% | -0.95 | 0.75 | 78.81% |
| Q3 2022 Q2Q % growth | -0.23 -428.57% | -0.65 | 0.42 | 64.77% |
| Q2 2022 Q2Q % growth | -0.13 40.91% | -0.70 | 0.57 | 81.53% |
| Q1 2022 Q2Q % growth | -0.25 76.85% | -0.68 | 0.43 | 63.42% |
| Q4 2021 Q2Q % growth | 0.11 -88.78% | -0.41 | 0.52 | 126.96% |
| Q3 2021 Q2Q % growth | 0.07 138.89% | -1.40 | 1.47 | 105.01% |
| Q2 2021 Q2Q % growth | -0.22 97.63% | -1.40 | 1.18 | 84.26% |
| Q1 2021 Q2Q % growth | -1.08 -199.08% | -1.40 | 0.32 | 22.71% |
| Q4 2020 Q2Q % growth | 0.98 116.84% | -1.08 | 2.06 | 190.64% |
| Q3 2020 Q2Q % growth | -0.18 97.35% | -3.21 | 3.03 | 94.39% |
| Q2 2020 Q2Q % growth | -9.29 -60.17% | -3.40 | -5.89 | -173.51% |
| Q1 2020 Q2Q % growth | 1.09 119.82% | -2.78 | 3.87 | 139.14% |
| Q4 2019 Q2Q % growth | -5.82 | -4.08 | -1.74 | -42.65% |
| Q3 2019 Q2Q % growth | -6.80 | -5.41 | -1.39 | -25.79% |
| Q2 2019 Q2Q % growth | -5.80 | -5.51 | -0.29 | -5.30% |
| Q1 2019 Q2Q % growth | -5.50 | -5.94 | 0.44 | 7.35% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | 500K | 500K | % | |
| Q3 2022 Q2Q % growth | 1M -80.00% | 1M | % | |
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q4 2021 Q2Q % growth | 500K | 500K | % | |
| Q3 2021 Q2Q % growth | 5M | 253.749K | 4.746M | 1,870.45% |
| Q2 2021 Q2Q % growth | 700K | 253.749K | 446.251K | 175.86% |
| Q1 2021 Q2Q % growth | 253.749K | -253.749K | -100.00% | |
| Q4 2020 Q2Q % growth | 500K -90.25% | 253.749K | 246.251K | 97.05% |
| Q3 2020 Q2Q % growth | -100.00% | 255K | -255K | -100.00% |
| Q2 2020 Q2Q % growth | -100.00% | 919.53K | -919.53K | -100.00% |
| Q1 2020 Q2Q % growth | -100.00% | 409.02K | -409.02K | -100.00% |
| Q4 2019 Q2Q % growth | 5.13M | 647.017K | 4.483M | 692.87% |
| Q3 2019 Q2Q % growth | 100K | 1.222M | -1.122M | -91.82% |
| Q2 2019 Q2Q % growth | 1.39M | 767.448K | 622.552K | 81.12% |
| Q1 2019 Q2Q % growth | 520K | 663.816K | -143.816K | -21.67% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -222.22% | -45% | 0% | 46.15% |
| Revenue | N/A | N/A | N/A | N/A |